Histone modification‐linked prognostic model for ovarian cancer reveals LBX2 as a novel growth promoter

Abstract

AbstractOvarian cancer (OC) is a deadly disease with limited treatment options and poor overall survival rates. This study aimed to investigate the role of histone modification‐related genes in predicting the prognosis of OC patients. Transcriptome data from multiple cohorts, including bulk RNA‐Seq data and single‐cell scRNA‐Seq data, were collected. Gene set enrichment analysis was used to identify enriched gene sets in the histone modification pathway. Differentially expressed genes (DEGs) between histone modification‐high and histone modification‐low groups were identified using Lasso regression. A prognostic model was constructed using five selected prognostic genes from the DEGs in the TCGA‐OV cohort. The study found enrichment of gene sets in the histone modification pathway and identified five prognostic genes associated with OC prognosis. The constructed risk score model based on histone modification‐related genes was correlated with immune infiltration of T cells and M1 macrophages. Mutations are more prevalent in the high‐risk group compared to the low‐risk group. Several drugs were screened against the model genes. Through in vitro experiments, we confirmed the expression patterns of the model genes. LBX2 facilitates the proliferation of OC. Histone modification‐related genes have the potential to serve as biomarkers for predicting OC prognosis. Targeting these genes may lead to the development of more effective therapies for OC. Additionally, LBX2 represents a novel cell proliferation promoter in OC carcinogenesis.